C-REACTIVE PROTEIN RANDOMIZED TRIALS AS PREDICTORS FOR USEFULNESS OF ASPIRIN v. MI, SUGGESTED BY STUDY; CRP ASSAY STUDY BY BEHRING MAY BE PUBLISHED IN 1998
This article was originally published in The Gray Sheet
Executive Summary
Inflammatory markers such as C-reactive protein should be studied in randomized trials for their utility in providing a method of "identifying people for whom aspirin is likely to be more or less effective" for reducing the risk of myocardial infarction, Paul Ridker, MD, Brigham & Women's Hospital, Boston, et al., state in a study published in the April 3 New England Journal of Medicine.